February 13, 2026 03:50 am (IST)
Follow us:
Emerging markets affect Dr Reddy's Laboratories' December quarter performance
Hyderabad, Feb 9 (IBNS) Dr Reddy's Laboratories Ltd announced its consolidated financial results on Tuesday for the quarter ended December 31, 2015, where it posted consolidated revenue of ₹39.7 billion, up 3 per cent from the same period in 2014, largely because the healthy performance in North America Generics (NAG), Europe and India were partially offset by emerging markets, which were impacted by unfavorable macro-economic conditions.
Revenues from the Global Generics segment for the reported quarter was ₹33.6 billion, up 7 per cent from the year-ago quarter, primarily driven by North America, Europe and India.
Revenues from the Pharmaceutical Services and Active Ingredients (PSAI) segment was ₹5.1 billion in the reported quarter, and declined by 17 per cent from the same quarter a year ago.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
Latest Headlines
HUL’s Q3 shock: 30% core profit drop sends shares reeling
Thu, Feb 12 2026
Lenskart rallies 11% as Q3 profit soars
Thu, Feb 12 2026
TCS, Honeywell join hands to enhance autonomous operations for buildings and industries with AI
Wed, Feb 11 2026
Capgemini teams up with Microsoft to power resilient, trusted digital transformation for clients with integrated sovereignty solutions
Wed, Feb 11 2026
Britannia shares jump 4% after Q3 results beat expectations!
Wed, Feb 11 2026
Govt opens BHEL OFS: 5% stake on sale – here’s what you need to know
Wed, Feb 11 2026